Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's

Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
Business

Listen to this article

0%

Ultragenyx Pharmaceuticalstock was hit with a flurry of downgrades after the biotechs rare-disease drug candidate failed to meet its main goal in a late-stage trial. Still, some analysts believe the … [+149 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected